Long-term outcome of treatment with ruxolitinib in myelofibrosis

N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Disease Progression
  • Humans
  • Janus Kinases / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Nitriles
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / mortality
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Survival Rate

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinases